Tags

Type your tag names separated by a space and hit enter

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.
Biol Psychiatry. 2002 Sep 01; 52(5):438-45.BP

Abstract

BACKGROUND

Studies in elderly patients demonstrate antipsychotic efficacy and favorable safety profiles for olanzapine. We report results from two placebo-controlled, double-blind studies of olanzapine for treatment of dopamimetic drug-induced psychosis in patients with Parkinson's disease (PD).

METHODS

Patients were treated with olanzapine or placebo for 4 weeks while dopamimetic therapy was held constant. Olanzapine was initiated at 2.5 mg/day, with 2.5-mg/day increases allowed every 3 to 4 days up to the maximum dose of 15 mg/day.

RESULTS

Olanzapine patients showed significant improvements from baseline on positive symptoms and most efficacy measures, but no significant treatment-group differences were observed. Olanzapine performed significantly worse than placebo in both studies on the Unified Parkinson's Disease Rating Scale (UPDRS) total, Motor, and Activities of Daily Living scales, but not the UPDRS Tremor item or Complications scores. Corrected QT interval, vital signs, and body weight were not significantly different from placebo.

CONCLUSIONS

These findings did not demonstrate superior efficacy of olanzapine for treatment of dopamimetic-induced psychosis in PD. The initial dose-titration schedule and mild baseline levels of psychosis may account for these findings. Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis.

Authors+Show Affiliations

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12242060

Citation

Breier, Alan, et al. "Olanzapine in the Treatment of Dopamimetic-induced Psychosis in Patients With Parkinson's Disease." Biological Psychiatry, vol. 52, no. 5, 2002, pp. 438-45.
Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002;52(5):438-45.
Breier, A., Sutton, V. K., Feldman, P. D., Kadam, D. L., Ferchland, I., Wright, P., & Friedman, J. H. (2002). Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biological Psychiatry, 52(5), 438-45.
Breier A, et al. Olanzapine in the Treatment of Dopamimetic-induced Psychosis in Patients With Parkinson's Disease. Biol Psychiatry. 2002 Sep 1;52(5):438-45. PubMed PMID: 12242060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. AU - Breier,Alan, AU - Sutton,Virginia K, AU - Feldman,Peter D, AU - Kadam,Deborah L, AU - Ferchland,Iris, AU - Wright,Padraig, AU - Friedman,Joseph H, PY - 2002/9/21/pubmed PY - 2002/12/7/medline PY - 2002/9/21/entrez SP - 438 EP - 45 JF - Biological psychiatry JO - Biol Psychiatry VL - 52 IS - 5 N2 - BACKGROUND: Studies in elderly patients demonstrate antipsychotic efficacy and favorable safety profiles for olanzapine. We report results from two placebo-controlled, double-blind studies of olanzapine for treatment of dopamimetic drug-induced psychosis in patients with Parkinson's disease (PD). METHODS: Patients were treated with olanzapine or placebo for 4 weeks while dopamimetic therapy was held constant. Olanzapine was initiated at 2.5 mg/day, with 2.5-mg/day increases allowed every 3 to 4 days up to the maximum dose of 15 mg/day. RESULTS: Olanzapine patients showed significant improvements from baseline on positive symptoms and most efficacy measures, but no significant treatment-group differences were observed. Olanzapine performed significantly worse than placebo in both studies on the Unified Parkinson's Disease Rating Scale (UPDRS) total, Motor, and Activities of Daily Living scales, but not the UPDRS Tremor item or Complications scores. Corrected QT interval, vital signs, and body weight were not significantly different from placebo. CONCLUSIONS: These findings did not demonstrate superior efficacy of olanzapine for treatment of dopamimetic-induced psychosis in PD. The initial dose-titration schedule and mild baseline levels of psychosis may account for these findings. Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis. SN - 0006-3223 UR - https://www.unboundmedicine.com/medline/citation/12242060/Olanzapine_in_the_treatment_of_dopamimetic_induced_psychosis_in_patients_with_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006322302013926 DB - PRIME DP - Unbound Medicine ER -